Benefit of ventriculoperitoneal cerebrospinal fluid shunting and intrathecal chemotherapy in neoplastic meningitis: a retrospective, case-controlled study

Clinical article

View More View Less
  • 1 Department of Neurosurgery, Brigham and Women's Hospital;
  • 2 Harvard Medical School, Boston, Massachusetts;
  • 3 Department of Neurosurgery, Milton S. Hershey Medical Center, Penn State College of Medicine, Hershey, Pennsylvania;
  • 4 Department of Neurosurgery, Huntsman Cancer Institute, University of Utah School of Medicine, Salt Lake City, Utah; and
  • 5 Department of Neurosciences, Moores Cancer Center, University of California, San Diego, La Jolla, California
Restricted access

Purchase Now

USD  $45.00

JNS + Pediatrics - 1 year subscription bundle (Individuals Only)

USD  $505.00

JNS + Pediatrics + Spine - 1 year subscription bundle (Individuals Only)

USD  $600.00
Print or Print + Online

Object

Neoplastic meningitis (NM) is a debilitating and increasingly frequent neurological complication of cancer characterized by infiltration of tumor cells into the leptomeninges and the subarachnoid space. Although NM is rarely curable, combined intrathecal chemotherapy and focal radiation can improve disease-related symptoms and survival. Hydrocephalus occurs in a significant proportion of patients, is associated with poor prognosis and reduced quality of life, and usually precludes the use of intrathecal therapy.

Methods

Since January of 2005, the authors have used a combined treatment approach for patients with both NM and hydrocephalus that employs a subcutaneously placed reservoir connected in series to an on/off valve and a ventriculoperitoneal shunt for both diversion of CSF and injection of intrathecal chemotherapy. They conducted a retrospective, case-controlled study from 2 independent institutions to review their experience.

Results

Twenty-four patients with NM and hydrocephalus underwent placement of a CSF reservoir-on/off valve-ventriculoperitoneal shunt (RO-VPS) construct. There was no perioperative mortality, and there were only 2 minor complications. One shunt failure and no shunt-associated infections were observed over a median of 28 weeks of follow-up. Symptomatic improvement and improved performance status were seen in 20 patients (83.3%) and were sustained over 6 months. Eighteen patients received intraventricular chemotherapy without unexpected toxicity, and cytological responses were found in 11 patients (61.1%). Median progression-free and overall survival was 14 and 31 weeks, respectively. Compared with a contemporaneous comparison group of 24 demographically matched patients with NM who underwent CSF reservoir placement only, those who received RO-VPS constructs (p = 0.02) and had primary diagnosis of breast cancer (p = 0.04) had significant advantage in overall survival.

Conclusions

A combined RO-VPS system is safe and practical to install, results in symptomatic improvement in most patients, and allows uncomplicated and effective administration of intrathecal chemotherapy in patients with NM. Cerebrospinal fluid diversion surgery should be considered in NM patients in conjunction with intrathecal and systemic treatments.

Abbreviations used in this paper: KPS = Karnofsky Performance Scale; NM = neoplastic meningitis; RO-VPS = reservoir–on/off valve–ventriculoperitoneal shunt.

JNS + Pediatrics - 1 year subscription bundle (Individuals Only)

USD  $505.00

JNS + Pediatrics + Spine - 1 year subscription bundle (Individuals Only)

USD  $600.00

Contributor Notes

Current affiliation for Dr. Friedlander: Department of Neurosurgery, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania.

Address correspondence to: Santosh Kesari, M.D., Ph.D., University of California, San Diego, Moores Cancer Center, 3855 Health Sciences Drive, MC 0819, La Jolla, California 92093-0819. email: skesari@ucsd.edu.

Please include this information when citing this paper: published online July 1, 2011; DOI: 10.3171/2011.5.JNS101768.

  • 1

    Berger MS, , Baumeister B, , Geyer JR, , Milstein J, , Kanev PM, & LeRoux PD: The risks of metastases from shunting in children with primary central nervous system tumors. J Neurosurg 74:872877, 1991

    • Search Google Scholar
    • Export Citation
  • 2

    Bernstein WB, , Kemp JD, , Kim GS, & Johnson VV: Diagnosing leptomeningeal carcinomatosis with negative CSF cytology in advanced prostate cancer. J Clin Oncol 26:32813284, 2008

    • Search Google Scholar
    • Export Citation
  • 3

    Bokstein F, , Lossos A, & Siegal T: Leptomeningeal metastases from solid tumors: a comparison of two prospective series treated with and without intra-cerebrospinal fluid chemotherapy. Cancer 82:17561763, 1998

    • Search Google Scholar
    • Export Citation
  • 4

    Boogerd W, , van den Bent MJ, , Koehler PJ, , Heimans JJ, , van der Sande JJ, & Aaronson NK, : The relevance of intraventricular chemotherapy for leptomeningeal metastasis in breast cancer: a randomised study. Eur J Cancer 40:27262733, 2004

    • Search Google Scholar
    • Export Citation
  • 5

    Brem SS, , Bierman PJ, , Brem H, , Butowski N, , Chamberlain MC, & Chiocca EA, : Central nervous system cancers. J Natl Compr Canc Netw 9:352400, 2011

    • Search Google Scholar
    • Export Citation
  • 6

    Bruna J, , González L, , Miró J, , Velasco R, , Gil M, & Tortosa A: Leptomeningeal carcinomatosis: prognostic implications of clinical and cerebrospinal fluid features. Cancer 115:381389, 2009

    • Search Google Scholar
    • Export Citation
  • 7

    Bruno MK, & Raizer J: Leptomeningeal metastases from solid tumors (meningeal carcinomatosis). Cancer Treat Res 125:3152, 2005

  • 8

    Chamberlain MC, & Glantz M: Ventriculoperitoneal shunt in patients with leptomeningeal metastasis. Neurology 66:783, 2006

  • 9

    Chowdhary S, & Chamberlain M: Leptomeningeal metastases: current concepts and management guidelines. J Natl Compr Canc Netw 3:693703, 2005

    • Search Google Scholar
    • Export Citation
  • 10

    DeAngelis LM, & Boutros D: Leptomeningeal metastasis. Cancer Invest 23:145154, 2005

  • 11

    DeAngelis LM, & Posner JB: Leptomeningeal metastases. Neurologic Complications of Cancer ed 2 New York, Oxford University Press, 2008. 240274

    • Search Google Scholar
    • Export Citation
  • 12

    Drappatz J, & Batchelor TT: Leptomeningeal neoplasms. Curr Treat Options Neurol 9:283293, 2007

  • 13

    Glantz MJ, , Hall WA, , Cole BF, , Chozick BS, , Shannon CM, & Wahlberg L, : Diagnosis, management, and survival of patients with leptomeningeal cancer based on cerebrospinal fluid-flow status. Cancer 75:29192931, 1995

    • Search Google Scholar
    • Export Citation
  • 14

    Glantz MJ, , Jaeckle KA, , Chamberlain MC, , Phuphanich S, , Recht L, & Swinnen LJ, : A randomized controlled trial comparing intrathecal sustained-release cytarabine (Depo-Cyt) to intrathecal methotrexate in patients with neoplastic meningitis from solid tumors. Clin Cancer Res 5:33943402, 1999

    • Search Google Scholar
    • Export Citation
  • 15

    Grossman SA, , Finkelstein DM, , Ruckdeschel JC, , Trump DL, , Moynihan T, & Ettinger DS: Randomized prospective comparison of intraventricular methotrexate and thiotepa in patients with previously untreated neoplastic meningitis. Eastern Cooperative Oncology Group. J Clin Oncol 11:561569, 1993

    • Search Google Scholar
    • Export Citation
  • 16

    Grossman SA, , Trump DL, , Chen DC, , Thompson G, & Camargo EE: Cerebrospinal fluid flow abnormalities in patients with neoplastic meningitis. An evaluation using 111indium-DTPA ventriculography. Am J Med 73:641647, 1982

    • Search Google Scholar
    • Export Citation
  • 17

    Harstad L, , Hess KR, & Groves MD: Prognostic factors and outcomes in patients with leptomeningeal melanomatosis. Neuro Oncol 10:10101018, 2008

    • Search Google Scholar
    • Export Citation
  • 18

    Hitchins RN, , Bell DR, , Woods RL, & Levi JA: A prospective randomized trial of single-agent versus combination chemotherapy in meningeal carcinomatosis. J Clin Oncol 5:16551662, 1987

    • Search Google Scholar
    • Export Citation
  • 19

    Kesari S, & Batchelor TT: Leptomeningeal metastases. Neurol Clin 21:2566, 2003

  • 20

    Mason WP, Leptomeningeal metastases. Schiff D, & Wen PY: Cancer Neurology in Clinical Practice Totowa, Humana Press, 2003. 115

  • 21

    Melisko ME, , Glantz M, & Rugo HS: New challenges and opportunities in the management of brain metastases in patients with ErbB2-positive metastatic breast cancer. Nat Clin Pract Oncol 6:2533, 2009

    • Search Google Scholar
    • Export Citation
  • 22

    Omuro AM, , Lallana EC, , Bilsky MH, & DeAngelis LM: Ventriculoperitoneal shunt in patients with leptomeningeal metastasis. Neurology 64:16251627, 2005

    • Search Google Scholar
    • Export Citation
  • 23

    Pace A, & Fabi A: Chemotherapy in neoplastic meningitis. Crit Rev Oncol Hematol 60:194200, 2006

  • 24

    Pavlidis N: The diagnostic and therapeutic management of leptomeningeal carcinomatosis. Ann Oncol 15:Suppl 4 iv285iv291, 2004

  • 25

    Sandberg DI, , Bilsky MH, , Souweidane MM, , Bzdil J, & Gutin PH: Ommaya reservoirs for the treatment of leptomeningeal metastases. Neurosurgery 47:4955, 2000

    • Search Google Scholar
    • Export Citation
  • 26

    Wasserstrom WR, , Glass JP, & Posner JB: Diagnosis and treatment of leptomeningeal metastases from solid tumors: experience with 90 patients. Cancer 49:759772, 1982

    • Search Google Scholar
    • Export Citation
  • 27

    Yoshida S, & Morii K: Intrathecal chemotherapy for patients with meningeal carcinomatosis. Surg Neurol 63:5255, 2005

  • 28

    Zada G, & Chen TC: A novel method for administering intrathecal chemotherapy in patients with leptomeningeal metastases and shunted hydrocephalus: case report. Neurosurgery 67:3 Suppl Operative onsE306onsE307, 2010

    • Search Google Scholar
    • Export Citation

Metrics

All Time Past Year Past 30 Days
Abstract Views 678 291 19
Full Text Views 287 63 9
PDF Downloads 134 40 2
EPUB Downloads 0 0 0